title: [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
abstract: Thiazolidinediones (TZD), which are widely used as insulin sensitizers, and fibrates, which are lipid-lowering drugs, are used in the treatment of dyslipidemia that commonly accompanies diabetes. Several reports suggest elevated levels of high-density lipoprotein (HDL) cholesterol, but the paradoxical reduction of HDL cholesterol level during single or combined TZD and fibrate therapies has been occasionally reported. Herein, we report a case of paradoxical decrease in HDL cholesterol and apolipoprotein A-1 levels during rosiglitazone and fenofibrate treatment for the first time in Korea. The patient was a 56-yr-old man presenting with type 2 diabetes mellitus and dyslipidemia. His HDL cholesterol and apolipoprotein A-1 levels returned to normal after the cessation of fenofibrate therapy. Since diabetes is an established risk factor of cardiovascular diseases, low HDL cholesterol can be a key cause of concern for patients with diabetes. Therefore, HDL cholesterol level should be determined before and after starting TZD and/or fibrate therapy in diabetic patients.
authors.affiliation: Department of Laboratory Medicine, Korea Cancer Center Hospital, Seoul, Korea.
authors.forename: Mijeong
authors.initials: M
authors.lastname: Im
authors.forename: Minki
authors.initials: M
authors.lastname: Kim
authors.forename: Jin Kyung
authors.initials: JK
authors.lastname: Lee
authors.forename: Yoon Hwan
authors.initials: YH
authors.lastname: Chang
authors.forename: Dong Young
authors.initials: DY
authors.lastname: Lee
authors.forename: Seok-Il
authors.initials: SI
authors.lastname: Hong
authors.forename: Yun Yong
authors.initials: YY
authors.lastname: Lee
authors.forename: Young Jun
authors.initials: YJ
authors.lastname: Hong
mesh_terms: D016632:Apolipoprotein A-I / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D011345:Fenofibrate